GLP-1 Market
LLY $1136.11 ▼ -0.2% NVO $42.53 ▼ -2.1% PFE $27.55 ▼ -0.6% VKTX $29.95 ▼ -5.0% KLRA $13.45 ▼ -2.2% GPCR $38.95 ▲ +1.3% RHHBY $54.90 ▲ +0.2%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Envarsus Product

Company
University of Alberta
Mechanism
Mechanism not yet reported
Route
Oral
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 16, 2026

Find a Clinical Trial Near Me

See recruiting studies for Envarsus Product and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT05242315

    Extended-Release Tacrolimus Following Liver Transplantation

    Not yet reported University of Alberta 94 participants Est. completion 2034-02-15 1 site
    Metabolic syndromeCardiovascular disease Other conditions: Liver Transplant; Complications, Renal Insufficiency, Immunosuppressant Adverse Reaction
    View official trial listing →
  • Terminated NCT NCT03689075

    Extended Release Versus Immediate Release Tacrolimus Following Renal Allograft Failure to Reduce Allosensitisation

    Not yet reported Imperial College Healthcare NHS Trust 35 participants Est. completion 2025-02-25 1 site
    Other conditions: Kidney Transplant Failure, Allosensitization, Immunosuppression
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Envarsus Product, Envarsus Oral Product

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.